Novo Nordisk will spend £115m over a 10-year period on a new research facility in Oxford.
The Danish company’s executive vice-president and chief science officer, Mads Thomsen, described the UK’s decision to leave the European Union as unfortunate, but said it should not affect its collaboration with Oxford.
Click here for the full Independent article
